The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC).
 
Caicun Zhou
Honoraria - Alice's Arc; Amoy Diagnostics; Anheart Therapeutics; Boehringer Ingelheim; CStone Pharmaceuticals; Hengrui Medicine; Innovent Biologics; Lilly; Luye Pharma; Merck Sharp & Dohme; QiLu Pharmaceutical; Roche; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Hengrui Medicine; Innovent Biologics; QiLu Pharmaceutical; TopAlliance BioSciences Inc
 
Silvia Novello
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - Sanofi
 
Pilar Garrido
Employment - Teva (I)
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim (I); Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Gebro Pharma (I); GlaxoSmithKline; IO Biotech; Janssen Biotech (I); Janssen Oncology; Lilly; Merck KGaA; MSD Oncology; Nordic Group (I); Novartis/Pfizer; Pfizer; Roche Pharma AG; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Janssen (I); Janssen Oncology; Medscape; MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Takeda; touchIME
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche Pharma AG
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Christophe Alfons Dooms
Consulting or Advisory Role - MSD Oncology (Inst)
Travel, Accommodations, Expenses - MSD (Inst)
 
Jorge Arturo Alatorre Alexander
Consulting or Advisory Role - BMS, ROCHE, AZ, TAKEDA, MSD,JANNSEN
Speakers' Bureau - BMS, ROCHE, AZ, TAKEDA, MSD,JANNSEN
Travel, Accommodations, Expenses - MSD, ROCHE, AZ
 
Niels Reinmuth
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Sanofi Aventis GmbH; Takeda
Travel, Accommodations, Expenses - Janssen
 
Adrienne M. Gilligan
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Nalin Payakachat
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Kim Cocks
Employment - Adelphi
Consulting or Advisory Role - Endomag Ltd., ArjoHuntleigh Healthcare Ltd.
 
Gill Worthy
No Relationships to Disclose
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pharma Mar, S.A.; RIKEN GENESIS CO., LTD.; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Haihe Biopharma Co., Ltd.; Janssen; Lilly Japan; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)